Overview
Since 20 September 2021 self-declared 'non-commercial organisations' are no longer required to provide a lobby budget. See above timeline for this registrant's historical lobby budget.
Lobbying Costs
None declared
Financial year: Jan 2023 - Dec 2023
Lobbyists (Full time equivalent)
0.45 Fte (3)
Lobbyists with EP accreditation
0
High-level Commission meetings
10
Lobbying Costs over the years
-
Info
European Organisation for Research and Treatment of Cancer (EORTC)
EU Transparency Register
70539554035-46 First registered on 20 Aug 2010
Goals / Remit
The European Organisation for Research and Treatment of Cancer (EORTC) has delivered investigator driven, changing practice clinical trials since 1962. Its mission is to improve survival and quality of life of cancer patients. The EORTC is a not-for-profit independent organisation performing multidisciplinary clinical research activities across tumor types. The EORTC aims to improve the standard of cancer treatment through the testing of more effective therapeutic strategies based on drugs, surgery and/or radiotherapy that are already in use. EORTC’s activities involve on a voluntary basis more than 3000 medical doctors and scientists from some 800 university hospitals in 35 countries. EORTC clinical trials are involving several thousands of cancer patients on a yearly basis. The EORTC operates on an independent basis, and in this capacity is able to work in partnership with the pharmaceutical industry in evaluating innovative molecules.
Main EU files targeted
- Regulation on clinical trials on medicinal products for human use.
- Regulation on Health Technology Assessment.
- Early access to medicines: PRIME, accelerated assessment, conditional market authorization.
- Good Clinical Practice implementation.
- General Data Protection Regulation.
- Regulation of the European Parliament and of the Council on in vitro diagnostic medical devices.
- Medical Device Regulation
- Euratom and radioprotection.
- EU Beating Cancer plan.
- EU Cancer Mission.
- EU Roadmap for a pharmaceutical strategy for Europe.
- Pharmaceutical strategy for Europe
- EU pharmaceutical legislation
- EU Partnership for Health Innovation.
- European Health Data SpaceAddress
Head Office
avenue Mounier, 83
Brussels 1200
BELGIUMEU Office
avenue Mounier, 83
Brussels 1200
BELGIUMWebsite
-
People
Total lobbyists declared
3
Employment time Lobbyists 25% 1 10% 2 Lobbyists (Full time equivalent)
0.45
Lobbyists with EP accreditation
No lobbyists with EP accreditations
Complementary Information
We are collaborating with VLASSEMBROUCK Consult/ABV Development for our interest representation activities (64547 euros in 2023)
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
Non-governmental organisations, platforms and networks and similar
-
Networking
Affiliation
European Cancer Organisation
European Forum for Good Clinical Practice
European Alliance for Personnalised Medicine
European Association for NeuroOncology
European Association of Urology
European School of Oncology
European Association of Urology
American Association for Cancer Research
European Society for Therapeutic Radiology and Oncology
European Society for Medical Oncology
American Society for Therapeutic Radiology and Oncology
International Society of Geriatric Oncology
International Society of Pediatric Oncology
International Union Against Cancer
International Network for Cancer Research and Treatment
Organisation of European Cancer Institutes
European Oncology Nursing Society
European Society of Pathology
European Society of RadiologyMember organisations
None declared
-
Financial Data
Interests represented
Does not represent commercial interests
Closed financial year
Jan 2023 - Dec 2023
Lobbying costs for closed financial year
Since 20 September 2021 self-declared 'non-commercial organisations' are no longer required to provide a lobby budget. See above timeline for this registrant's historical lobby budget.
Total organisational budget in closed year
57,000€
Major funding types in closed year
Grants, Other, Public funding, Donations
Funding types "other" information
EORTC raised 46 million euros incomes in 2023. 39% is coming from grants from the industry, 14% is coming from grants obtained from public and private non-for profit organizations, 25% from expert services and license for Quality of Life research tools, 9% from translation of Quality of Life questionnaires, 5% from subsidies, 5% from congresses/events and 3% from other sources.
Major contributions in closed year
Type Name Amount Contribution Bayer 7,710,000€ Other financial info
None declared
-
EU Structures
Groups (European Commission)
None declared
Groups (European Parliament)
Cancer
Communication activities
Participation in workshops and conference involving EU institutions officials. Position statement in collaboration with stakeholders groups such European Cancer Organisation, European Alliance for Personalised Medicine, BioMedAlliance, Rare Cancers Europe, EFGCP, European Data in Health Research Alliance, European Federation of Pharmaceutical Industries, FIPRA.
EORTC is represented in the following working groups: Commission Expert Group on Clinical Trials, Commission HTA stakeholders pool, EMA CTIS new delivery model, EMA EV- Expert Working Group, Accelerating clinical trials in the EU (ACT EU) initiative, .
The EORTC is co-chairing the Cancer Medicines Forum together with the European Medicines Agency (EMA) which aims to advance treatment optimisation for approved cancer medicines. This includes by identifying and prioritizing research questions as well as policy issues emerging from the academic communityOther activities
None declared
Meetings
Meetings
10 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.
1 July 2024: We have noted that some meetings are appearing in duplicate, ie. some meetings seem to be listed twice. This seems to be because the Commission changes some element of a meeting data after the meeting has first been listed, which causes LobbyFacts to register it as a new meeting. We are investigating further.
-
Date 11 Jun 2024 Location Online Subject Meeting on Europe’s Beating Cancer Plan and EU Policy on cancer; research and treatment optimisation Cabinet Cabinet of Commissioner Stella Kyriakides Attending - Stella Kyriakides (Commissioner)
- Tove Ernst (Cabinet member)
-
Date 11 Jun 2024 Location Online Subject Meeting on research and treatment optimisation Cabinet Cabinet of Commissioner Stella Kyriakides Attending - Tove Ernst (Cabinet member)
- Stella Kyriakides (Commissioner)
-
Date 11 Mar 2022 Location Brussels, virtual Subject Discussion on Europe's Beating Cancer Plan and breast cancer Cabinet Cabinet of Commissioner Stella Kyriakides Portfolio Health Attending - Tove Ernst (Cabinet member)
-
Date 24 Feb 2021 Location Brussels - virtual meeting Subject Exchange of views on Europe’s Beating Cancer Plan, the EU Pharmaceutical Strategy and the availability of medicines. Cabinet Cabinet of Commissioner Stella Kyriakides Portfolio Health Attending - Stella Kyriakides (Commissioner)
- Tove Ernst (Cabinet member)
-
Date 03 Nov 2020 Location Brussels - virtual call Subject Exchange of views on Europe’s Beating Cancer Plan Cabinet Cabinet of Commissioner Stella Kyriakides Portfolio Health Attending - Tove Ernst (Cabinet member)
-
Date 19 Feb 2020 Location Brussels Subject challenges of documenting robust evidence for the use of cancer treatments DG Health and Food Safety Attending - Anne Bucher (Director-General)
-
Date 05 Feb 2020 Location Brussels Subject Discussion on Cancer and Europe's Beating Cancer Plan Cabinet Cabinet of Commissioner Stella Kyriakides Portfolio Health Attending - Tove Ernst (Cabinet member)
- Stella Kyriakides (Commissioner)
Other Lobbyists -
Date 03 May 2018 Location Brussels Subject HTA Cabinet Cabinet of Commissioner Vytenis Andriukaitis Portfolio Health & Food Safety Attending - Vytenis Andriukaitis (Commissioner)
- Annika Nowak (Cabinet member)
Other Lobbyists -
Date 16 Apr 2018 Location Brussels Subject Discussion Cancer Research DG Health and Food Safety Attending - Xavier Prats Monné (Director-General)
-
Date 05 May 2017 Location Brussels Subject Clinical research Cabinet Cabinet of Commissioner Vytenis Andriukaitis Portfolio Health & Food Safety Attending - Annika Nowak (Cabinet member)